Company / Operating Cash Flow
BioNexus Gene Lab Corp Operating Cash Flow History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$1.8M
FY2025
5-year range
-$2.1M / $551.8K
FY2021-FY2025
Trend
+12.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow returned to growth in FY2025 after 2 years of decline, reaching -$2M.
Based on SEC 10-K filings.
-$2M in FY2025.
Remained stable around -$2M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow increased 12.2% year-over-year.
- Peak operating cash flow was recorded in FY2020.
- Lowest operating cash flow in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score 5.27 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.8M | +12.2% |
| FY2024 | -$2.1M | -14.9% |
| FY2023 | -$1.8M | -430.2% |
| FY2022 | $551.8K | +5923.6% |
| FY2021 | $9.2K | -98.3% |
| FY2020 | $552.7K | +354.4% |
| FY2019 | -$217.3K | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026